News
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Poxel Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below.
Transgene will meet
Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new serum-based blood test that can
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Savara Added to the NASDAQ Biotechnology Index
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia announced today the submission of its Investigational New Drug application (IND) to the U.S. Food and Drug
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 30, 2024. The
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel])
ICON Wins Industry Accolades from TIME Magazine, Forbes and Financial Times in Second Half of 2023
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation (CRO), finishes the second half of 2023 with positive recognition as a top-rated employer and
Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") today announced that on December 15, 2023 the U.S. Food and Drug Administration (FDA) has
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On December 11
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Pfizer Declares First-Quarter 2024 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.42 for the first-quarter 2024 dividend
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Pfizer Completes Acquisition of Seagen
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes
Pfizer Provides Full-Year 2024 Guidance
Pfizer Inc. (NYSE:PFE) today provided its full-year 2024 guidance(1)(6), which includes the expected financial impact from the Seagen transaction.
Accompanying presentation can be found at www.p